Skip to main content

Table 1 Clinical and pharmacological characteristics of the patients.

From: Decreased pre-surgical CD34+/CD144+ cell number in patients undergoing coronary artery bypass grafting compared to coronary artery disease-free valvular patients

 

CABG

Valvular

P

Number

51

49

-

Age

64.65 ± 13.34

72.7 ± 10.4

0.106

Sex (Women, %)

8 (15.69%)

22 (44.89%)

0.001*

BMI (kg/m2)

26.91 ± 0.43

26.51 ± 0.57

0.5726§

EF (%)

62.51 ± 1.84

69.2 ± 1.41

0.006§

Tobacco

12 (23.53%)

9 (18.37%)

0.698*

Alcohol intake

15 (29.41%)

14 (28.57%)

0.898*

Hypertension

31 (60.78%)

27 (55.10%)

0.486*

Dyslipidemia

31 (60.78%)

16 (32.65%)

0.003*

Diabetes

24 (47.06%)

5 (10.20%)

< 0.001*

ACEI/ARB

25 (49.02%)

19 (38.77%)

0.302*

Beta blockers

16 (31.37%)

9 (18.37%)

0.133*

Calcium blockers

8 (15.69%)

10 (20.41%)

0.539*

Antiplatelet drugs

33 (64.71%)

8 (16.33%)

< 0.001*

Statins

34 (66.67%)

11 (22.45%)

< 0.001*

Nitrates

16 (31.37%)

2 (4.08%)

< 0.001*

Oral antidiabetics

16 (31.37%)

2 (4.08%)

< 0.001*

Insulin

13 (25.49%)

1 (2.04%)

< 0.001*

MI < 30 days

16 (31.37%)

0 (0%)

< 0.001*

EuroSCORE

3.6 ± 0.4194

5.7 ± 0.4

< 0.001*

  1. * = Chi-squared test, § = Student's t test, = U Mann-Whiney-Wilcoxon test
  2. BMI: body mass index; EF: ejection fraction; MI; myocardial infarction